Mood disorders iii chapter 7 march 12 2014 psyc 2340 abnormal psychology brett deacon ph d
Download
1 / 21

Mood Disorders III (Chapter 7) March 12, 2014 PSYC 2340: Abnormal Psychology Brett Deacon, Ph.D. - PowerPoint PPT Presentation


  • 94 Views
  • Uploaded on
  • Presentation posted in: General

Mood Disorders III (Chapter 7) March 12, 2014 PSYC 2340: Abnormal Psychology Brett Deacon, Ph.D. Or, Everything You Ever Wanted to Know about Antidepressant Medications. Announcements. Exam #2 handed back Midterm grades turned in. From Last Class. Genetic influences on depression

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about 'Mood Disorders III (Chapter 7) March 12, 2014 PSYC 2340: Abnormal Psychology Brett Deacon, Ph.D. ' - laurel-morales


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Mood disorders iii chapter 7 march 12 2014 psyc 2340 abnormal psychology brett deacon ph d
Mood Disorders III(Chapter 7)March 12, 2014PSYC 2340: Abnormal PsychologyBrett Deacon, Ph.D.



Announcements
Announcements Medications

  • Exam #2 handed back

  • Midterm grades turned in


From last class
From Last Class Medications

  • Genetic influences on depression

  • Chemical imbalance theory

    • Popularity

    • Accuracy

    • Effects on depressed individuals


Treatments for depression
Treatments for Depression Medications

  • Cognitive therapy

    • Supported by large body of evidence

    • Directly targets errors in thinking

    • Teaches patients to:

      • 1. Identify thinking errors

      • 2. Dispute them

      • 3. Generate more accurate ways of thinking

      • 4. Generate practical solutions to problems


Treatments for depression1
Treatments for Depression Medications

  • Behavioral activation

    • Increases contact with reinforcing events

    • Equal to or more effective than cognitive therapy (Jacobson et al., 1996; Dimidjian et al., 2006)

  • Interpersonal psychotherapy

    • Addresses problematic relationship functioning associated with depression

  • Physical exercise

  • “Antidepressant” medications


Comparison of four depression treatments
Comparison of Four Depression Treatments Medications

  • Dimidjian et al. (2006)

  • Compared Paxil, placebo, cognitive therapy, and behavioral activation during 8 weeks of treatment for 241 depressed patients

  • Examined low vs. high severity patients separately

    • Why?


Comparison of four depression treatments1
Comparison of Four Depression Treatments Medications

  • Dropout rates:

    • Cognitive therapy = 13.3%

    • Behavioral activation = 16.3%

    • Paxil = 44.4%

  • For “low severity” participants, Paxil was not significantly more effective than placebo pill

    • Placebo was 85.7% as effective as Paxil on self-reported depressive symptoms and 85.6% as effective on clinician-rated symptoms


Mood disorders iii chapter 7 march 12 2014 psyc 2340 abnormal psychology brett deacon ph d
Cognitive therapy vs. Behavioral Activation vs. Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

Dobson et al., 2008


Psychotherapy vs antidepressants long term cost effectiveness
Psychotherapy vs. Antidepressants: Antidepressants: Long-Term Maintenance of Gains After Treatment DiscontinuationLong-Term Cost-Effectiveness

Dobson et al., 2008


Adverse effects of antidepressants
Adverse Effects of Antidepressants Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

  • Drug-induced treatment resistance and chronic depressive symptoms

  • Long-term use of antidepressant medication, even when immediately beneficial, may produce a state of “tardive dysphoria” in 30% to 50% of patients characterized by loss of drug efficacy with symptom exacerbation, increased risk of relapse, and diminished and potentially irreversible responsiveness to subsequent drug treatment (El-Mallakh et al., 2011; Fava, 2003; Fava & Offidani, 2010)


Prior antidepressant exposure and treatment response leykin et al 2007
Prior Antidepressant Exposure and Treatment Response ( Antidepressants: Long-Term Maintenance of Gains After Treatment DiscontinuationLeykin et al., 2007)


Medication vs psychotherapy for depression a summary
Medication vs. Psychotherapy for Depression: A Summary Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

  • Antidepressants are as effective as psychosocial treatments in the short term for mild, moderate, and severe depression

  • The small advantage of antidepressants over placebo is the same with psychotherapy – what does this mean?

  • Psychotherapy is far more effective in preventing relapse

  • Psychotherapy is less expensive (vs. brand name antidepressants)

  • Psychotherapy is preferred by patients

  • More patients refuse or drop out of pharmacotherapy; psychotherapy has no adverse physical effects

  • Psychotherapy is difficult to access and not used by many


60 minutes story on antidepressants
60 Minutes Story on Antidepressants Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

  • http://www.youtube.com/watch?v=Zihdr36WVi4


Antidepressants in the news
Antidepressants in the News Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

  • Fallout from the 60 Minutes story on the placebo effect in antidepressants

  • http://ww2.psych.org/MainMenu/Newsroom/NewsReleases/2012-News-Releases/60-Minutes-Segment-on-Antidepressants-Irresponsible-and-Dangerous.aspx?FT=.pdf

  • http://www.huffingtonpost.com/dr-harold-koplewicz/placebo-effect_b_1332416.html

  • http://www.madinamerica.com/2012/02/the-american-psychiatric-associations-response-to-60-minutes-evidence-based-response-or-propaganda/

  • http://www.psychologytoday.com/blog/the-skeptical-sleuth/201202/cbs-60-minutes-news-treating-depression-sorting-through-the-confu-0

  • http://www.psychologytoday.com/blog/the-skeptical-sleuth/201203/irving-kirsch-d-j-vu-all-over-again

  • http://www.psychologytoday.com/blog/who-we-are/201203/demonizing-kirsch-will-get-us-nowhere

  • http://www.psychologytoday.com/blog/our-empathic-nature/201203/the-media-war-anti-depressants


Drug treatments for mood disorders
Drug Treatments for Mood Disorders Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

  • Antidepressant medications

  • CDC study: http://www.cdc.gov/nchs/data/databriefs/db76.htm

  • Key findings include:

    • Eleven percent of Americans aged 12 years and over take antidepressant medication.

    • More than 60% of Americans taking antidepressant medication have taken it for 2 years or longer, with 14% having taken the medication for 10 years or more.


Many americans take antidepressant medications
Many Americans Take Antidepressant Medications Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

Overall

average

CDC, 2011


Drug treatments for mood disorders1
Drug Treatments for Mood Disorders Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

  • Newer generation antidepressants (e.g., SSRIs)

    • First SSRI was Prozac (1987)

2010

1990


Basis of prozac s fda approval
Basis of Prozac’s FDA Approval Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

  • A note about FDA requirements for approval

  • 5 Prozac studies involving 1,132 depressed patients

  • Each trial lasted between 4 - 8 weeks

  • The trials included a 1- to 2-wk washout period during which patients were given placebo, prior to random assignment. Those whose scores improved 20% or more were excluded from the study prior to random assignment.

  • Replacement of patients who investigators determined were not improving after 2 weeks was allowed in three Prozac trials.

  • Many patients were given a sedative medication to minimize adverse effects.

  • Investigators coded suicide attempts as “overdose” to minimize apparent adverse effects.

  • Depressive symptoms were measured only using the clinician-rated Hamilton Rating Scale for Depression. Self-report symptoms were not assessed.


Basis of prozac s fda approval1
Basis of Prozac’s FDA Approval Antidepressants: Long-Term Maintenance of Gains After Treatment Discontinuation

  • 3 trials showed a statistically significant advantage of Prozac vs. placebo; 2 did not

  • Averaged across all trials:

    • Average improvement with Prozac = 8.30 points on HAM-D

    • Average improvement with placebo = 7.34 points on HAM-D

  • 89% of drug effect duplicated with placebo

  • The FDA approved Prozac for adults in 1987


ad
  • Login